Carles Domenech

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Understanding Ibrilatazar's mechanism of action: Addressing concerns about autophagy in cancer Therapy.

Understanding Ibrilatazar's mechanism of action: Addressing concerns about autophagy in cancer Therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 08, 2025

Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.

Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.

Journal: Frontiers in oncology

Published: December 03, 2024

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 06, 2024

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Journal: BMC cancer

Published: July 29, 2024

Type designation and redescription of Scolopendraspinosissima Kraepelin, 1903 (Scolopendromorpha, Scolopendridae), with remarks on related taxa.

Type designation and redescription of Scolopendraspinosissima Kraepelin, 1903 (Scolopendromorpha, Scolopendridae), with remarks on related taxa.

Journal: ZooKeys

Published: June 11, 2024

Taxonomic and nomenclatural reassessment of the Iberian Peninsula's nomina obscura, Scolopendraviridipes Dufour, 1820 and S.chlorotes L. Koch in Rosenhauer, 1856 (Chilopoda, Scolopendromorpha, Scolopendridae).

Taxonomic and nomenclatural reassessment of the Iberian Peninsula's nomina obscura, Scolopendraviridipes Dufour, 1820 and S.chlorotes L. Koch in Rosenhauer, 1856 (Chilopoda, Scolopendromorpha, Scolopendridae).

Journal: ZooKeys

Published: March 02, 2024

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.

Journal: BMC cancer

Published: January 02, 2024

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.

Journal: Frontiers in oncology

Published: May 13, 2022

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.

Journal: Cancer communications (London, England)

Published: January 31, 2022

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.

A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 10, 2020

The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.

The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis.

Journal: Cell death & disease

Published: June 12, 2020

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

Journal: Autophagy

Published: May 14, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026